Update of dalbavancin spectrum and potency in the USA: Report from the SENTRY Antimicrobial Surveillance Program (2011)

Diagnostic Microbiology and Infectious Disease

Volumn 75, Issue 3, 2013, Pages 304-307

  Jones, Ronald N ^a   Sader, Helio S ^a   Flamm, Robert K ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Activity; Dalbavancin; SENTRY; Surveillance

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES; UNITED STATES;

ANTI-BACTERIAL AGENTS; CLINDAMYCIN; DAPTOMYCIN; DRUG EVALUATION; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STREPTOCOCCUS; TEICOPLANIN; UNITED STATES; VANCOMYCIN;

EID: 84873740876     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.11.024     Document Type: Article

References (23)

1. Anderegg T.R., Biedenbach D.J., Jones R.N. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent Gram-positive activity. J Clin Microbiol 2003, 41:2795-2796.
2. Andes D., Craig W.A. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007, 51:1633-1642.
3. Biedenbach D.J., Bell J.M., Sader H.S., Turnidge J.D., Jones R.N. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother 2009, 53:1260-1263.
4. Biedenbach D.J., Jones R.N. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007). Diagn Microbiol Infect Dis 2009, 64:177-184.
5. Biedenbach D.J., Ross J.E., Fritsche T.R., Sader H.S., Jones R.N. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J Clin Microbiol 2007, 45:998-1004.
6. Buckwalter M., Dowell J.A. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 2005, 45:1279-1287.
7. Clinical and Laboratory Standards Institute (CLSI) M100-S22. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement 2012, CLSI, Wayne, PA.
8. Clinical and Laboratory Standards Institute (CLSI) M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement 2013, CLSI, Wayne, PA.
9. Dowell J.A., Goldstein B.P., Buckwalter M., Stogniew M., Damle B. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J Clin Pharmacol 2008, 48:1063-1068.
10. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013 Available at, Accessed October 1, 2012. http://www.eucast.org/clinical_breakpoints/.
11. Fritsche T.R., Rennie R.P., Goldstein B.P., Jones R.N. Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using Gram-positive organisms. J Clin Microbiol 2006, 44:2988-2990.
12. Goldstein B.P., Jones R.N., Fritsche T.R., Biedenbach D.J. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagn Microbiol Infect Dis 2006, 54:83-87.
13. Goldstein E.J., Citron D.M., Warren Y.A., Tyrrell K.L., Merriam C.V., Fernandez H.T. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother 2006, 50:2875-2879.
14. Jauregui L.E., Babazadeh S., Seltzer E., Goldberg L., Krievins D., Frederick M., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005, 41:1407-1415.
15. Jones RN, Farrell DJ, Moet GJ, Sader HS. Potency of dalbavancin tested against 37,258 Gram-positive cutaneous pathogens from USA medical centers (2006-2009). In: 51st ICAAC, September 12-15, 2011. Abstr. E-1323. Chicago, IL, USA. 2011.
16. Jones R.N., Fritsche T.R., Sader H.S., Goldstein B.P. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother 2005, 17:593-600.
17. Jones R.N., Stilwell M.G., Sader H.S., Fritsche T.R., Goldstein B.P. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis 2006, 54:149-153.
18. Jones R.N., Streit J.M., Fritsche T.R. Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int J Antimicrob Agents 2004, 23:197-199.
19. Rennie R.P., Koeth L., Jones R.N., Fritsche T.R., Knapp C.C., Killian S.B., et al. Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent. J Clin Microbiol 2007, 45:3151-3154.
20. Seltzer E., Dorr M.B., Goldstein B.P., Perry M., Dowell J.A., Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003, 37:1298-1303.
21. Streit J.M., Fritsche T.R., Sader H.S., Jones R.N. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004, 48:137-143.
22. Streit J.M., Sader H.S., Fritsche T.R., Jones R.N. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis 2005, 53:307-310.
23. Zhanel G.G., Calic D., Schweizer F., Zelenitsky S., Adam H., Lagace-Wiens P.R., et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010, 70:859-886.